MX392642B - Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. - Google Patents
Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion.Info
- Publication number
- MX392642B MX392642B MX2017000699A MX2017000699A MX392642B MX 392642 B MX392642 B MX 392642B MX 2017000699 A MX2017000699 A MX 2017000699A MX 2017000699 A MX2017000699 A MX 2017000699A MX 392642 B MX392642 B MX 392642B
- Authority
- MX
- Mexico
- Prior art keywords
- expression
- protein
- development
- antibody performance
- production hosts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Ecology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27116809P | 2009-07-17 | 2009-07-17 | |
| PCT/US2010/042302 WO2011009058A2 (en) | 2009-07-17 | 2010-07-16 | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX392642B true MX392642B (es) | 2025-03-19 |
Family
ID=43450243
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000699A MX392642B (es) | 2009-07-17 | 2010-07-16 | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. |
| MX2012000803A MX2012000803A (es) | 2009-07-17 | 2010-07-16 | Selección y desarrollo integrados simultáneos del desempeño y la expresión de proteínas/anticuerpos en hospederos de producción. |
| MX2015005873A MX347654B (es) | 2009-07-17 | 2010-07-16 | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012000803A MX2012000803A (es) | 2009-07-17 | 2010-07-16 | Selección y desarrollo integrados simultáneos del desempeño y la expresión de proteínas/anticuerpos en hospederos de producción. |
| MX2015005873A MX347654B (es) | 2009-07-17 | 2010-07-16 | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US8859467B2 (https=) |
| EP (6) | EP3156485B1 (https=) |
| JP (3) | JP6193570B2 (https=) |
| KR (5) | KR20190017070A (https=) |
| CN (2) | CN107090031A (https=) |
| AU (5) | AU2010273974B2 (https=) |
| BR (1) | BR112012001171B1 (https=) |
| CA (2) | CA3034484A1 (https=) |
| DK (5) | DK3156485T3 (https=) |
| ES (3) | ES2701931T3 (https=) |
| HU (1) | HUE029328T2 (https=) |
| IN (1) | IN2012DN00737A (https=) |
| MX (3) | MX392642B (https=) |
| MY (2) | MY160472A (https=) |
| PL (2) | PL2907873T3 (https=) |
| PT (1) | PT3042957T (https=) |
| SG (3) | SG10201700096VA (https=) |
| WO (1) | WO2011009058A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201700096VA (en) * | 2009-07-17 | 2017-02-27 | Bioatla Llc | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| ES2741175T3 (es) | 2010-07-16 | 2020-02-10 | Bioatla Llc | Nuevos métodos de evolución de proteínas |
| AU2015242961B2 (en) * | 2010-07-16 | 2017-03-02 | Bioatla, Llc | Novel methods of protein evolution |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| EP2773964A4 (en) * | 2011-11-03 | 2015-06-24 | Stc Biolog Inc | METHOD FOR DETERMINING THE PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS |
| HK1221908A1 (zh) | 2013-04-29 | 2017-06-16 | Adimab, Llc | 多特异(polyspecificity)试剂，其制备方法和用途 |
| EP3447493B1 (en) * | 2014-01-07 | 2020-05-13 | Bioatla, LLC | Proteins targeting orthologs |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| ES2913205T3 (es) * | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| WO2016004242A1 (en) * | 2014-07-01 | 2016-01-07 | Stc Biologics, Inc. | A method for development of recombinant proteins with fingerprint like similarity to the reference product |
| DK4074735T3 (da) | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| WO2016036916A1 (en) | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| EP3262217A4 (en) | 2015-02-24 | 2018-07-18 | BioAtla LLC | Conditionally active biological proteins |
| PE20181363A1 (es) * | 2015-09-23 | 2018-08-27 | Genentech Inc | Variantes optimizadas de anticuerpos anti-vegf |
| WO2017078839A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
| PL3455261T3 (pl) | 2016-05-13 | 2022-12-12 | Bioatla, Inc. | Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania |
| AU2018301393B2 (en) | 2017-07-11 | 2025-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| CN113924118A (zh) | 2019-04-18 | 2022-01-11 | 百时美施贵宝公司 | 在低ph下具有增强的结合特异性的伊匹单抗变体 |
| US20240124889A1 (en) | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN111048154B (zh) * | 2019-12-10 | 2023-06-06 | 上海药明生物技术有限公司 | 一种抗体表位作图的方法 |
| CN111462815B (zh) * | 2020-03-27 | 2023-05-02 | 上海祥耀生物科技有限责任公司 | 一种抗体库的构建方法及装置 |
| US11506060B1 (en) * | 2021-07-15 | 2022-11-22 | Honeywell International Inc. | Radial turbine rotor for gas turbine engine |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| JP2025528068A (ja) | 2022-08-03 | 2025-08-26 | ボイジャー セラピューティクス インコーポレイテッド | 血液脳関門を通過させるための組成物及び方法 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4957858A (en) | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
| US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| ATE92538T1 (de) | 1988-01-21 | 1993-08-15 | Genentech Inc | Verstaerkung und nachweis von nukleinsaeuresequenzen. |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| JP2856804B2 (ja) | 1988-03-24 | 1999-02-10 | ユニバーシティ オブ アイオワ リサーチ ファウンデイション | 標識された相補的核酸プローブを開裂する触媒反応の補因子としての活性に基づく核酸配列検出のための触媒ハイブリッド形成系 |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP1361273A3 (en) | 1992-11-24 | 2004-02-11 | G.D. Searle & Co. | Interleukin-3 (IL-3) multiple mutation polypeptides |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US20030219752A1 (en) * | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US8137906B2 (en) | 1999-06-07 | 2012-03-20 | Sloning Biotechnology Gmbh | Method for the synthesis of DNA fragments |
| US7033781B1 (en) | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| CN100522242C (zh) | 2001-02-19 | 2009-08-05 | 默克专利有限公司 | 具有降低的免疫原性的人工蛋白质 |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| WO2002092780A2 (en) * | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| BRPI0412007A (pt) * | 2003-06-27 | 2006-08-15 | Bioren Inc | mutagênese look-through |
| GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| EP2617827A1 (en) * | 2007-03-26 | 2013-07-24 | Celexion, LLC | Method for displaying engineered proteins on a cell surface |
| US7947495B2 (en) | 2007-11-01 | 2011-05-24 | Abbott Biotherapeutics Corp. | Immunoglobulin display vectors |
| JP5513398B2 (ja) | 2007-11-02 | 2014-06-04 | ザ スクリプス リサーチ インスティチュート | 非天然アミノ酸を含有する蛋白質を使用する指向的進化 |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
| SG10201700096VA (en) | 2009-07-17 | 2017-02-27 | Bioatla Llc | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts |
| FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2010
- 2010-07-16 SG SG10201700096VA patent/SG10201700096VA/en unknown
- 2010-07-16 WO PCT/US2010/042302 patent/WO2011009058A2/en not_active Ceased
- 2010-07-16 DK DK16196481.2T patent/DK3156485T3/en active
- 2010-07-16 MX MX2017000699A patent/MX392642B/es unknown
- 2010-07-16 KR KR1020197004078A patent/KR20190017070A/ko not_active Ceased
- 2010-07-16 ES ES16196481T patent/ES2701931T3/es active Active
- 2010-07-16 DK DK16157965.1T patent/DK3042957T3/en active
- 2010-07-16 PT PT161579651T patent/PT3042957T/pt unknown
- 2010-07-16 MY MYPI2012000207A patent/MY160472A/en unknown
- 2010-07-16 CN CN201611220313.3A patent/CN107090031A/zh active Pending
- 2010-07-16 CA CA3034484A patent/CA3034484A1/en active Pending
- 2010-07-16 EP EP16196481.2A patent/EP3156485B1/en active Active
- 2010-07-16 MX MX2012000803A patent/MX2012000803A/es active IP Right Grant
- 2010-07-16 ES ES16157965.1T patent/ES2652340T3/es active Active
- 2010-07-16 CA CA2768247A patent/CA2768247C/en active Active
- 2010-07-16 CN CN2010800388394A patent/CN102625848A/zh active Pending
- 2010-07-16 KR KR1020217002264A patent/KR20210013294A/ko not_active Ceased
- 2010-07-16 EP EP15156820.1A patent/EP2907873B1/en active Active
- 2010-07-16 EP EP16157965.1A patent/EP3042957B1/en active Active
- 2010-07-16 KR KR1020127003948A patent/KR101823872B1/ko active Active
- 2010-07-16 EP EP10800618.0A patent/EP2454376B1/en active Active
- 2010-07-16 DK DK18183032.4T patent/DK3406717T3/da active
- 2010-07-16 US US13/384,362 patent/US8859467B2/en active Active
- 2010-07-16 PL PL15156820.1T patent/PL2907873T3/pl unknown
- 2010-07-16 BR BR112012001171-5A patent/BR112012001171B1/pt active IP Right Grant
- 2010-07-16 MY MYPI2015002586A patent/MY173037A/en unknown
- 2010-07-16 SG SG2012003356A patent/SG177687A1/en unknown
- 2010-07-16 DK DK19210622.7T patent/DK3636759T3/da active
- 2010-07-16 AU AU2010273974A patent/AU2010273974B2/en active Active
- 2010-07-16 ES ES15156820.1T patent/ES2581318T3/es active Active
- 2010-07-16 KR KR1020187002028A patent/KR20180010347A/ko not_active Ceased
- 2010-07-16 MX MX2015005873A patent/MX347654B/es unknown
- 2010-07-16 DK DK15156820.1T patent/DK2907873T3/en active
- 2010-07-16 EP EP19210622.7A patent/EP3636759B1/en active Active
- 2010-07-16 HU HUE15156820A patent/HUE029328T2/en unknown
- 2010-07-16 EP EP18183032.4A patent/EP3406717B1/en active Active
- 2010-07-16 PL PL16157965T patent/PL3042957T3/pl unknown
- 2010-07-16 SG SG10201505075TA patent/SG10201505075TA/en unknown
- 2010-07-16 JP JP2012520813A patent/JP6193570B2/ja active Active
- 2010-07-16 KR KR1020217042385A patent/KR20220002712A/ko not_active Ceased
-
2011
- 2011-11-17 US US13/298,559 patent/US10106788B2/en active Active
-
2012
- 2012-01-25 IN IN737DEN2012 patent/IN2012DN00737A/en unknown
-
2014
- 2014-09-09 US US14/481,564 patent/US10047357B2/en active Active
-
2015
- 2015-05-06 JP JP2015094521A patent/JP6193913B2/ja active Active
- 2015-10-16 AU AU2015243076A patent/AU2015243076B2/en active Active
-
2017
- 2017-05-15 AU AU2017203243A patent/AU2017203243B2/en active Active
- 2017-06-02 JP JP2017109593A patent/JP6681131B2/ja active Active
-
2018
- 2018-08-31 US US16/118,673 patent/US10920216B2/en active Active
-
2019
- 2019-05-31 AU AU2019203813A patent/AU2019203813B2/en active Active
-
2021
- 2021-01-27 US US17/159,936 patent/US11976381B2/en active Active
- 2021-05-19 AU AU2021203220A patent/AU2021203220B2/en active Active
-
2024
- 2024-03-21 US US18/612,054 patent/US20240263354A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392642B (es) | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| PE20160528A1 (es) | Anticuerpos | |
| MY176026A (en) | Methods and composions comprising purified recombinant polypeptides | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| BR112017023131A2 (pt) | anticorpos anti- fcrn | |
| EA201201435A1 (ru) | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| MX2009012747A (es) | Produccion de proteina recombinante en celulas ebx de aves. | |
| AR107078A1 (es) | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso | |
| EA201590671A1 (ru) | Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли | |
| EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
| CO7160115A2 (es) | Proteinas de unión a antigeno que se unen a pd-l1 | |
| ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
| EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
| CL2012002081A1 (es) | Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria. | |
| PH12018501335A1 (en) | Novel generation of antigen-specific tcrs | |
| CY1121795T1 (el) | Αντισωματα κατα toy cd52 | |
| WO2012068317A3 (en) | Methods for producing recombinant proteins | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| AR095268A1 (es) | ANTICUERPOS HUMANOS QUE SE UNEN AL FACTOR a DE LA NECROSIS (TNF-a) HUMANO Y MÉTODOS PARA PREPARARLOS | |
| EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
| EA201000273A1 (ru) | Белок-предшественник тиопептида, кодирующий его ген и его применение | |
| MX381725B (es) | Medicamento que comprende anticuerpo anti-fosfolipasa d4. |